학술논문
Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children
Document Type
Article
Author
Sas, D.J.; Magen, D.; Hayes, W.; Shasha-Lavsky, H.; Michael, M.; Schulte, I.; Sellier-Leclerc, A.-L.; Lu, J.; Seddighzadeh, A.; Habtemariam, B.; McGregor, T.L.; Fujita, K.P.; Frishberg, Y.; Bacchetta, J.; Baudouin, V.; Becker-Cohen, R.; Tzvi Behr, S.; Ben-Shalom, E.; Berdaguer, M.; Bockenhauer, D.; Cochat, P.; Coenen, M.; Cramer, C.H.; Deschênes, G.; Dossier, C.; Doye, E.; Feldman, L.F.; Hohenadel, M.; Kaguelidou, F.; Zebegret, I.L.; Lieske, J.C.; Maisin, A.; Milliner, D.S.; Plonsky Toder, M.; Pollack, S.; Portefaix, A.; Ranchin, B.; Rinat, C.; Safdar, A.; Schalk, G.; Srivaths, P.R.; Tran, C.L.; Van't Hoff, W.; Weinbrand-Goichberg, J.; Weissman, I.
Source
In: Genetics in Medicine . (Genetics in Medicine, March 2022, 24(3):654-662)
Subject
Language
English
ISSN
15300366
10983600
10983600